Patents Assigned to Bayer Aktiengesellschaft
  • Publication number: 20210163474
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 3, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Kai LOVIS, Winfried JOENTGEN
  • Patent number: 11019821
    Abstract: The invention relates to novel compounds of the formula (I) in which Aa, Ab, Ac, Ad, Q, R1 and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 1, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Publication number: 20210147504
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Jan TEBBE, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210146284
    Abstract: The invention relates to solutions for the monitoring, process control and supervision of a solid filtration, particularly the washing process of said solid in a filtration system, and particularly to a method for monitoring and controlling a process for filtering and washing a solid in a filtration device for cake filtration, wherein at least one measuring device is applied in or to the filtrate outlet of the filtration device, which measures the at least one parameter value of a filtrate flow from the filtration device for cake filtration at least during the washing process.
    Type: Application
    Filed: April 9, 2019
    Publication date: May 20, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Kathrin Annette ENGELHARDT, Reinhard GROSS
  • Publication number: 20210137094
    Abstract: A weed control vehicle may include a sensor for acquiring data relating to at least one location of an environment using at least one sensor of the vehicle. The sensor data is provided to a processing unit of the vehicle. The processing unit determines a distance sensing result for each location of the at least one location. The processing unit controls at least one actuator to move at least one boom of the vehicle. At least one weed control unit is attached to the at least one boom. The processing unit controls the at least one actuator to move the at least one boom on the basis of the distance sensing result for each location of the at least one location.
    Type: Application
    Filed: March 29, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Sergio JIMENEZ TARODO, Michael KILIAN, James HADLOW, Virginie GIRAUD, Thomas ARIANS
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210127686
    Abstract: The present invention relates to formulation for fungal spores which increases storage stability of said fungal spores comprising a liquid water-soluble formulation comprising fungal spores, at least one plant oil, at least one antioxidant and optionally at least one rheology-modifying agent. Further, the invention relates to a method for controlling phytopathogenic fungi, insects and/or nematodes in or on a plant, for enhancing growth of a plant or for increasing plant yield or root health comprising applying an effective amount of the present formulation.
    Type: Application
    Filed: June 12, 2019
    Publication date: May 6, 2021
    Applicants: Bayer Aktiengesellschaft, BAYER CROPSCIENCE BIOLOGICS GMBH
    Inventors: Ulrike HILSCHER, Oliver GAERTZEN
  • Publication number: 20210128723
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (lb) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 6, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventor: Antje Margret WENGNER
  • Patent number: 10993439
    Abstract: Provided are compounds of the formula (I) which are suitable for controlling animal pests, including arthropods and in particular insects, arachnids and nematodes, and in which the structural elements R1, p, T and G have the meanings given in the description, as are processes for their preparation and their use as insecticides.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 4, 2021
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Markus Heil, Laura Hoffmeister, Matthew Webber, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Patent number: 10998086
    Abstract: Method for configuring a production plant designed for performing at least one chemical reaction, wherein the production plant has at least one plant module, and a plant module for configuring the production plant, which plant module is chosen from a module database running on a first server system and/or is combined from a component database running on a second server system.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: May 4, 2021
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Christoph Fleischer-Trebes, Bojan Niko Broetz
  • Publication number: 20210121447
    Abstract: The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).
    Type: Application
    Filed: May 10, 2019
    Publication date: April 29, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Peter Sandner, Peter Kolkhof, Ilka Mathar, Stefanie Breitenstein
  • Publication number: 20210118143
    Abstract: The present disclosure pertains to the analysis of the cardiac region in CT images. Provided herein are a method, a computer system and a computer program product for the segmentation of the cardiac region in CT images.
    Type: Application
    Filed: October 19, 2020
    Publication date: April 22, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Franco FOIS, Wei LIAO, Daniel RECHSTEINER
  • Publication number: 20210113504
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Patent number: 10981932
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 20, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • Patent number: 10981935
    Abstract: The invention relates to novel compounds of the formula (I) in which Aa, Ab, R1, R2, R3, R4, R5 and n have the meanings mentioned above, to the use thereof as acaricides and/or insecticides for controlling animal pests and to methods and intermediates for the preparation thereof.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 20, 2021
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Dominik Hager, Ruediger Fischer, Laura Hoffmeister, Nina Kausch-Busies, Marc Mosrin, David Wilcke, Matthieu Willot, Kerstin Ilg, Sascha Eilmus, Ulrich Goergens, Andreas Turberg
  • Patent number: 10968216
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
  • Patent number: 10961220
    Abstract: The present invention relates to a method for preparing substituted imidazolyl carboxyamides of the formula (II) proceeding from compounds of the formula (I) via an intermediate of the formula (IIIa) or (IIIb) in which the structural elements specified in the formulae (I), (II), (IIIa) and (IIIb) have the definitions stated. Furthermore, the invention relates to the compounds of the formulae (IIIa) and (IIIb).
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: March 30, 2021
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Marc Mosrin, Matthieu Willot, Johannes-Rudolf Jansen
  • Publication number: 20210085656
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 25, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN
  • Publication number: 20210085262
    Abstract: The present invention relates to the field of accompanying patients and alleviating the symptoms of a disease, particularly in patients suffering from cardiac insufficiency. The invention relates to a method and a system for monitoring the state of health of a large number of patients.
    Type: Application
    Filed: January 9, 2019
    Publication date: March 25, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Frank KRAMER, Wilfried DINH
  • Publication number: 20210079056
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER